Bayer to Showcase Radiology Pipeline Advances at ECR 2026

Bayer to Showcase Radiology Pipeline Advances at ECR 2026

By, Admin 29 January 2026

Bayer will present new data and technology advancements from its comprehensive radiology portfolio at the European Congress of Radiology (ECR) 2026, taking place March 4–8 in Vienna, Austria.

The company will highlight progress across:

  • Next-generation contrast agent development
  • Advanced injector systems
  • Data-driven connectivity and workflow solutions that support smarter, more efficient radiology practice

Gadoquatrane takes center stage

A major focus of Bayer’s scientific program will be gadoquatrane, an investigational low-dose macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI.

New presentations will include phase III subgroup analyses demonstrating the efficacy and safety of gadoquatrane in:

  • Abdominal MRI
  • Cardiac MRI
  • Magnetic resonance angiography (MRA)
  • Central nervous system (CNS) imaging

Additional phase II and phase III data will also detail pharmacokinetics and imaging performance. Across the clinical development program, gadoquatrane has been evaluated at 0.04 mmol Gd/kg body weight, representing a 60% reduction in gadolinium dose compared with standard macrocyclic agents dosed at 0.1 mmol Gd/kg.

Regulatory momentum for gadoquatrane

Bayer announced positive topline results in 2025 from all studies in the pivotal phase III QUANTI program. Marketing authorization applications have now been submitted in:

  • United States
  • European Union
  • Japan
  • China

Additional global filings are planned in the coming months.

Leadership perspectives

Nelson Ambrogio, president of radiology at Bayer, said the company looks forward to engaging with the radiology community and presenting cutting-edge science that translates into improved patient care.

Minerva Becker, ECR 2026 Congress President, emphasized the importance of collaboration between academia and industry in advancing radiology research and bringing innovation into clinical practice.

Selected gadoquatrane sessions at ECR 2026

Key scientific sessions featuring gadoquatrane include:

  • Neuroimaging and CNS imaging: Pharmacokinetics, imaging comparability, and regulatory-supporting population PK modeling
  • Cardiac MRI: Phase III subgroup analysis of low-dose contrast-enhanced body MRI
  • Abdominal MRI: Phase III subgroup analysis of safety and efficacy
  • Vascular imaging and MRA: Stability assessments and one-year follow-up of gadolinium presence and distribution

Poster presentations will further explore gadoquatrane’s role in contrast-enhanced MR angiography and detailed pharmacokinetic profiling.

Bayer’s radiology business at a glance

Bayer’s radiology portfolio includes:

  • Contrast agents for CT, MRI, X-ray, and PET
  • Injector systems for precise administration
  • Informatics and digital solutions for workflow optimization

In 2024, Bayer’s radiology products generated €2.1 billion in sales.

Why this matters?

Lower-dose, high-performance contrast agents like gadoquatrane aim to:

  • Maintain diagnostic image quality
  • Reduce gadolinium exposure
  • Support safer, more sustainable imaging practices

Bayer’s presence at ECR 2026 underscores its strategy to pair formulation innovation with digital connectivity to shape the next generation of radiology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!